JP Stock MarketDetailed Quotes

4503 Astellas Pharma

Watchlist

1542.5
+22.5+1.48%

20min DelayNot Open Dec 20 15:30 JST

2.79TMarket Cap162.88P/E (Static)

Astellas Pharma Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Astellas Pharma H1 FY2025 Earnings Date

Currency：JPYOct 30, 2024

	Estimate (YoY)	Actual (YoY)	Vs Estimate (% Chg)
Revenue	916.18B	935.62B	+19.44B
Beat Est.	+19.43%	+21.96%	+4.57%
EPS	--	40.91	--
		+105.58%

Analyst Rating

Buy

Dec 9, 2024

Astellas Pharma Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 5 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: JPY

Actual

Estimate

Date	Period	Revenue/Estimate	Earnings Call
--	2025/Q4	-- / 414.065B	--
--	2025/Q3	-- / 448.790B	--
Oct 30, 2024	2025/Q2	462.497B / 425.282B	--
Aug 1, 2024	2025/Q1	473.124B / 411.415B	--
Apr 25, 2024	2024/Q4	414.602B / 381.093B	--

DatePeriodRevenue/EstimateEarnings Call

--2025/Q4-- / 414.065B--

--2025/Q3-- / 448.790B--

Oct 30, 20242025/Q2462.497B / 425.282B--

Aug 1, 20242025/Q1473.124B / 411.415B--

Apr 25, 20242024/Q4414.602B / 381.093B--

Unlock Free Earnings Estimates

Open Account

Astellas Pharma Earnings Reports

Astellas Pharma: Confirmation letter

Nov 6 12:52

Astellas Pharma: Half Year Report - Term 20 (2024/04/01 - 2025/03/31)

Nov 6 12:51

Astellas Pharma: Supplementary financial information for the 2nd quarter (interim period) of the fiscal year ending March 31, 2025

Oct 30 14:00

Astellas Pharma: Financial results briefing materials for the 2nd quarter (interim period) of the fiscal year ending March 31, 2025

Oct 30 14:00

Symbol Price % Chg

Beauty Kadan Holdings

KODAMA CHEMICAL INDUSTRY

4222

440 +22.22%

See the daily top gainer.

Analysis

Analyst Rating

Updated: Dec 9, 2024

Buy

Strong Buy

40.00%
Buy

13.33%
Hold

40.00%
Underperform

6.67%
Sell

0.00%

Price Target

No Data